Patients without progressive disease following induction therapy were randomised ( @:@ ratio , using a minimisation method with biased-coin assignment balancing on ECOG performance status -LSB- @ vs @ -RSB- , response to induction chemoradiotherapy -LSB- complete response plus near complete response vs partial response and stable disease -RSB- , and institution ) to receive either three further cycles of consolidation etoposide plus cisplatin or irinotecan plus cisplatin ( intravenous irinotecan @ mg/m ( @ ) on days @ , @ , @ ; intravenous cisplatin @ mg/m ( @ ) on day @ ) .